$-0.02 EPS Expected for Theratechnologies Inc (TH)

September 3, 2017 – By Peter Erickson

Investors wait Theratechnologies Inc (TSE:TH) to report on October, 3. its quarterly earnings Wall Street analysts expect $-0.02 earnings per share, down $0.03 or 300.00 % from last year’s $0.01 same quarter earnings. Theratechnologies Inc’s Wall Street analysts see -84.62 % EPS growth, taking into account the $-0.13 EPS reproted in the previous quarter, The stock increased 1.04% or $0.08 on September 1, reaching $7.75. About 45,533 shares traded. Theratechnologies Inc (TSE:TH) has 0.00% since September 3, 2016 and is . It has underperformed by 16.70% the S&P500.

Theratechnologies Inc. is a specialty pharmaceutical company. The company has market cap of $578.00 million. The Firm addresses medical needs to promote healthy living among human immunodeficiency virus patients. It currently has negative earnings. The Company’s products include EGRIFTA and Ibalizumab.

More notable recent Theratechnologies Inc (TSE:TH) news were published by: Marketwired.com which released: “Theratechnologies Inc.: Ibalizumab 24-Week Pivotal Phase III Study Results …” on January 18, 2017, also Medgadget.com with their article: “HIV Associated Lipodystrophy Syndrome Market to Register Substantial Expansion …” published on May 03, 2017, Marketwired.com published: “Theratechnologies Regains Rights to EGRIFTA® (tesamorelin for injection) in …” on May 01, 2014. More interesting news about Theratechnologies Inc (TSE:TH) were released by: Seekingalpha.com and their article: “Theratechnologies Has An Unheralded Blockbuster” published on November 15, 2016 as well as Marketwired.com‘s news article titled: “Theratechnologies Issues Reminder Regarding Warrant Expiry” with publication date: August 03, 2017.